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N-Myristoyl transferase-mediated labelling using a substrate modified with an azide or alkyne tag 
is described as an efficient and site-selective method for the introduction of a bioorthogonal tag at 
the N-terminus of a recombinant protein. The procedure may be performed in vitro, or in a single 
over-expression/tagging step in vivo in bacteria; tagged proteins may then be captured using 
Staudinger-Bertozzi or ‘click’ chemistry protocols to introduce a secondary label  for downstream 10 
analysis. The straightforward synthesis of the chemical and molecular biological tools described 
should enable their use in a wide range of N-terminal labelling applications.
Introduction 
Protein labelling using bioorthogonal ligation chemistry 
Site-specific labelling of proteins with chemical or fluorescent 15 
probes is a prerequisite for many established and emerging 
techniques in chemical and cell biology.1-3 Protein labelling 
technology has been revolutionised by the discovery of highly 
selective, water-compatible reactions that permit 
bioorthogonal ligation of a synthetic probe at a defined site 20 
that bears a small chemical tag such as an azide, alkyne or 
aldehyde.4 Bioorthogonal ligation chemistry has proven to be 
robust,5 and has been used in a remarkable range of 
applications for labelling proteins and other biomolecules 
both in vitro and in vivo.6 However, there remains a need for 25 
methods that allow the introduction of suitable tags into a 
protein in both an efficient and site-specific manner, 
particularly in live cells.  
 Two distinct approaches have been developed to address 
this problem, which enable introduction of tagged sites at 30 
either the DNA or protein level. Expanded codon usage, first 
pioneered by the Schultz group, enables incorporation of a 
tagged amino acid at an arbitrary number of specific sites 
encoded in the parent gene.7,8 Alternatively, the protein can be 
modified post-translationally to introduce a chemical 35 
modification bearing a bioorthogonal tag at a suitable 
consensus motif. A growing range of enzymes have been 
adapted for use in this approach, including farnesyl 
transferases,9,10 biotin ligase11 and formylglycine-generating 
enzyme.12 Despite the great potential of these techniques, 40 
their adoption for general labelling applications can be limited 
by the need for relatively complex synthetic and biochemical 
protocols.  
 We recently communicated13 a straightforward and 
practical transferase-based technique that permits site-specific 45 
in vitro and in vivo generation of N-terminal azide-tagged 
recombinant protein, and subsequent labelling with 
Staudinger-Bertozzi ligation chemistry.14 Here we report this 
work in full, and extend the scope to encompass transferase-
mediated in vivo production of alkynyl-tagged proteins and 50 
subsequent bioorthogonal labelling with [3 + 2] azide-alkyne 
cycloaddition (‘click’ chemistry).4 
Myristoyl-CoA:protein N-myristoyl transferase (NMT) 
N-Myristoylation at an N-terminal glycine is a constitutive 
co-translational modification that occurs in all eukaryotic 55 
cells, and contributes to regulation of signalling and 
trafficking by modulating protein-membrane and protein-
protein associations.15 Myristoyl-CoA:protein N-myristoyl 
transferase (NMT), the enzyme that catalyses myristoylation, 
has been characterised in a wide range of organisms, from 60 
yeast to humans.16-21 Comprehensive studies by Gordon et al. 
found that the specificity of Saccharomyces cerevisiae NMT 
(ScNMT) towards fatty acyl-coenzyme A (CoA) analogues is 
limited to acids that closely mimic myristoyl-CoA (2, Fig. 1), 
particularly with respect to chain length (~14 heteroatoms) 65 
and flexibility.22-24 Nevertheless, this early work suggested 
that ScNMT tolerates the introduction of some functionality in 
the acyl chain of the myristoyl-CoA substrate and recent 
reports have also described the use of modified myristate for 
non-radioactive metabolic labelling in mammalian cell 70 
lines.25,26 Encouraged by this work, we decided to investigate 
transfer of alkyne- and azide-modified myristate analogues by 
NMT as a means for introducing a bioorthogonal ligation tag 
at the N-terminus of proteins bearing an N-terminal 
myristoylation motif. 75 
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Fig. 1 Myristic acid 1, myristoyl-CoA 2 and myristic acid analogues 3 
and 4 designed and used in this study. 
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Results and Discussion 
Design and synthesis of tagged substrates for NMT 
A well-characterised and widely-used NMT cloned from 
Candida albicans (CaNMT)18 was selected as the azido- or 
alkynyl-myristate transfer agent. This enzyme exhibits 5 
excellent stability, activity and solubility, and may be over-
expressed and purified without the need for an affinity tag.27 
Two myristic acid analogues were designed, incorporating an 
azide (3) or alkyne (4) at the terminal position (Fig. 1) so as to 
mimic the chain length and flexibility of the natural substrate 10 
as closely as possible. In 11-azido undecanoic acid 3, three 
carbon atoms were replaced by the three nitrogen atoms of the 
azide, whilst in tetradec-13-ynoic acid 4, the terminal single 
bond was replaced by a triple bond. It was hypothesised that 
these relatively minor modifications would not have a 15 
significant impact on the affinity of the acyl-CoA substrate for 
CaNMT.18,27 The long alkyl chain in 3 and 4 would also be 
expected to act as a flexible linker between protein and tag, 
potentially serving to improve the accessibility of the tag for 
subsequent modification.  20 
 3 And 4 were synthesised in one or two steps starting from 
commercially-available ω-bromo acids (Scheme 1). Simply 
reacting 11-bromo undecanoic acid with sodium azide in 
DMSO furnished 3 in excellent yield, whilst a sequence of 
bromine displacement from 12-bromo dodecanoic acid with 25 
lithium trimethylsilyl acetylide followed by base-mediated 
deprotection gave 4 in good overall yield. Each analogue was 
then converted to the corresponding acyl-CoA thioester by 
activation with 1,1'-carbonyldiimidazole (CDI) and reaction 
with CoASH (trisodium salt) under basic conditions. 30 
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Scheme 1 Synthesis of myristic acid analogues 3 and 4, and their 
corresponding CoA thioester analogues 5 and 6. Reagents and conditions: 
i) NaN3, DMSO; ii) a) CDI, THF, b) CoASH, THF–NaHCO3 (0.5 M); 
iii) TMS-Acetylene, nBuLi, THF–HMPA, –78 °C; iv) K2CO3, MeOH. 35 
In vitro azido- and alkynyl-tagging of a peptide substrate 
A series of initial experiments were performed to demonstrate 
that 5 and 6 are indeed substrates for CaNMT. A model 
peptide substrate H-GLYVSRLFNRLFQKK-NH2 (7) bearing 
a canonical N-terminal myristoylation motif of general 40 
sequence GXXXS (X = any amino acid)28-30 was synthesised 
by standard Fmoc/tBu solid phase peptide synthesis (SPPS). 
7 Corresponds to the N-terminal region of Plasmodium 
falciparum ADP ribosylation factor 1 (PfARF1),16,31-33 which 
we have shown previously to be a substrate for CaNMT. The 45 
corresponding N-terminal azido-myristoylated (8) and 
alkynyl-myristoylated (9) analogues of 7 were synthesised by 
capping the resin with 3 or 4 respectively prior to cleavage. 
Incubation of equimolar quantities of 7 and one of the two 
acyl-CoA substrates (5 or 6) in the presence of a catalytic 50 
quantity of CaNMT (0.25 mol %) in a suitable buffer for up to 
2 hours was sufficient for complete transfer of the acyl group 
to the target peptide as determined by HPLC (Fig. 2). In each 
case 7 was rapidly consumed during the reaction. 
Interestingly, transfer from the alkyne-tagged myristoyl-CoA 55 
analogue 6 appears to be at least two-fold faster than from the 
azide-tagged substrate 5, which may reflect a higher affinity 
for the selective myristoyl-CoA binding pocket. Both 
analogues are transferred at a rate comparable to that of the 
native substrate 2.27 60 
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Fig. 2 HPLC traces showing in vitro transfer of A) 3 or B) 4 (B) via CoA 
ester 5, or 6 to the N-terminus of peptide 7 (H-GLYVSRLFNRLFQKK-
NH2), over reaction times of T = 0 up to 120 min. Products were 
identified by reference to authentic samples of 8 and 9 prepared by 65 
chemical synthesis (see Experimental). 
In vivo azido- and alkynyl-tagging of a recombinant protein 
Having confirmed that CaNMT will transfer the tagged acyl 
group from acyl-CoA substrates 5 and 6 in vitro, we next 
sought to apply this technique for tagging and subsequent 70 
labelling of a recombinant protein.† Previous work has shown 
that E. coli engineered to co-express NMT and a substrate 
protein provides a practical system to study myristoylation 
in vivo in isolation from other cellular processes.34,35 Whilst 
bacteria are competent to convert myristic acid to the 75 
activated CoA thioester via acyl-CoA synthetase36 they do not 
possess protein N-myristoyl transferases, which are an enzyme 
class exclusive to eukaryotes. Furthermore, in common with 
eukaryotes, bacteria express methionine aminopeptidase 
(MetAP),37 which is required to strip the leader methionine 80 
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from a substrate protein to reveal the requisite N-terminal 
glycine. These properties make the bacterial co-expression 
system a useful tool for the production of N-myristoylated 
proteins.  
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Fig. 3 Schematic overview of the E. coli co-expression system applied to 
azide and alkyne tagging of a protein in vivo. 
 In the co-expression approach bacteria are transformed with 
a pair of expression constructs containing the NMT and 
substrate sequences together with orthogonal antibiotic 10 
resistance genes; under double antibiotic selection the bacteria 
retain both plasmids. Simultaneous feeding with myristic acid 
and induction in the presence of isopropyl β-D-1-
thiogalactopyranoside (IPTG) causes the bacteria to express 
both proteins, and myristic acid is transferred to the substrate 15 
inside the bacteria. We hypothesised that acids 3 and 4 could 
be used directly in such a co-expression system to enable the 
generation of tagged protein, as outlined in Fig. 3. The 
success of this approach would depend on both sufficient 
uptake of the myristic acid analogues and their acceptance as 20 
substrates by bacterial acyl-CoA synthetase. This 
methodology would offer two key advantages over the in vitro 
approach:  
• It removes the requirement for synthesis of the acyl-CoA 
thioester, thus limiting the reagents required to cheap and 25 
readily available compounds. 
• Expression and isolation of the target tagged protein can 
be achieved in a single experiment, without the need for 
separate purification and isolation of either NMT or 
substrate. 30 
A set of capture reagents were designed and synthesised to 
enable the detection of protein tagging via bioorthogonal 
ligation of a biotin label to either azide- or alkyne-tagged 
targets (Scheme 2). The syntheses described here are 
significantly simplified from those reported in previous 35 
studies, and can be carried out in as few as three steps, 
starting from commercially-available Biotin-PEG NovaTag™ 
resin. In each case, an acid bearing the appropriate capture 
group (pent-4-ynoic acid 10, 4-azidobutyric acid 11 or 
3-(diphenylphosphino)-4-(methoxycarbonyl) benzoic acid 12) 40 
was preactivated with HATU and coupled in 4-fold excess 
relative to resin loading. Subsequent cleavage (95% aqueous 
TFA) and purification by RP-HPLC afforded the 
corresponding capture reagents bearing an azide (13), alkyne 
(14) or triarylphosphine (15) moiety in good overall yield.   45 
O
H
N
O
N
Fmoc
O N
H
O
S
NH
HN
O
H
H
3 4
Biotin-PEG NovaTagTM Resin
H3CO
Ph2P
H3CO2C
O
OH
N
H
Cap
O N
H
O
S
NH
HN
O
H
H
3 4
i - iii
OH
O
OH
O
N3
10 11 12
13 : Cap = pent-5-ynoyl
14 : Cap = 4-azidobutanoyl
15 : Cap = 3-(diphenylphosphino)-4-(methoxycarbonyl) benzoyl
 
Scheme 2 Synthesis of capture reagents 13, 14 and 15. i) 20% 
piperidine/DMF; ii) acid 10, 11 or 12, HATU, DIPEA; iii) 95% TFA(aq). 
 Expression constructs for CaNMT under ampicillin 
selection and PfARF1 under kanamycin selection were 50 
co-transformed into E. coli BL21 (DE3) competent cells, and 
induced for 4 hours at 37 °C in the presence of 1 mM IPTG 
together with 0.5 mM 3 or 4. After cell lysis and 
centrifugation the fraction containing soluble protein was 
reacted with the appropriate capture reagent (see 55 
Experimental) and analysed by SDS-polyacrylamide gel 
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electrophoresis (SDS-PAGE). The PfARF1 construct bears a 
C-terminal His6 tag, which enables verification by Western 
blot with αHis6-HRP conjugate (Fig. 4A), whilst biotinylated 
protein was visualised after blotting with NeutrAvidin™-HRP 
conjugate (Fig. 4B–C). Negative control cells expressing only 5 
CaNMT (lanes 3, 4 and 8) or PfARF1 (lanes 7 and 8), cells 
fed with myristic acid rather than a tagged analogue (lane 5) 
and uncaptured lysates (lane 6) were run for comparison.  
20
30
20
30
20
30
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PfARF1 wt G2A wt G2A wt wt – – wt
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Fig. 4 In vivo transfer of an azide or alkyne tag to recombinant PfARF1. 10 
A: cells fed with azido acid 3 visualised by Western blot with anti-His6-
HRP conjugate; B: Cells fed with 3 and captured with reagent 13 (except 
lane 9, captured with reagent 15), visualised with NeutrAvidin™-HRP 
conjugate; C: Cells fed with 4 and captured with reagent 14 (except lane 
9, experiment not performed), visualised with NeutrAvidin™-HRP 15 
conjugate. A known endogenous biotinylated E. coli protein of ca. 22 kDa 
is observed in all samples in B and C (marked by *).38 
 As shown in Fig. 4, transfer of both azido- and alkynyl- 
acids are observed only in the presence of CaNMT, and 
subsequent capture is highly specific for the tagged substrate. 20 
No significant capture of either myristoylated PfARF1 or 
endogenous E. coli proteins is observed under the conditions 
used. Furthermore, no labelling is observed in cells over-
expressing CaNMT with a PfARF1[G2A] mutant protein 
bearing an alanine at the N-terminus (Fig. 4B and C, lanes 2 25 
and 4), demonstrating that the present method is highly site-
specific for an N-terminal Gly residue. The band observed 
below PfARF1 (Fig. 4B and C, lanes 1–9) is biotin carboxyl 
carrier protein (BCCP), a well-characterised endogenous 
biotinylated E. coli protein.38,‡ Interestingly, the efficiency of 30 
capture by [3 + 2] cycloaddition (or ‘click’ chemistry) appears 
to be superior to that of capture with the Staudinger-Bertozzi 
reagent under the conditions used, an observation that 
corroborates a previous comparative study of bioorthogonal 
ligation approaches.5 [3 + 2] capture of azide tagged protein 35 
with 14 is also superior to that of alkyne tagged protein with 
13 under identical conditions, an observation noted previously 
by Cravatt and co-workers.39 This is likely due to the 
enhancement in rate in the presence of a large excess of 
activated alkyne in the case of capture using reagent 14; in the 40 
case of capture with 13, the rate is presumably limited by the 
relatively lower concentration of activated alkynyl-protein. 
Conclusions 
In summary, we have reported a novel method for in vivo 
co-translational site-specific introduction of an azide or 45 
alkyne chemical tag during expression of a recombinant 
protein. Subsequent elaboration via click chemistry has been 
used to introduce a biotin label for visualisation by gel 
electrophoresis, and in principle it should be possible to adapt 
this approach for the introduction of a wide range of labels. 50 
The canonical N-myristoylation motif GXXXS has been 
shown to direct N-terminal tagging to a single specific site. In 
addition to providing a convenient and potentially general 
method for N-terminal recombinant protein labelling, this 
system also provides a useful model system and proof-of-55 
principle for in vivo ‘tagging-by-substrate’ studies aimed at 
elucidating the myristoylated proteome (or ‘myristome’) in 
cells in culture or in multicellular organisms.25,26 Post- and co-
translational methods for protein labelling also present the 
potential for orthogonal multi-site protein labelling in 60 
combination with other enzymatic techniques. We envisage 
that the system presented here could be combined with related 
approaches reported for the post-translational introduction of 
tags,9,10,12 to enable site-specific labelling of a protein with a 
FRET pair, for example. Work is ongoing in our labs to 65 
extend the methodology presented here for the labelling of 
other recombinant proteins for biophysical and bioconjugate 
studies. 
Experimental 
Materials and Methods 70 
All solvents were purchased from BDH and used without 
further purification. All reagents, unless otherwise stated, 
were purchased at the highest quality available from Sigma-
Aldrich and used without further purification. NMR spectra 
were recorded in 5 mm tubes calibrated to the residual solvent 75 
peak stated, on Bruker AV-400 and AV-500 spectrometers. 
COSY and HMQC correlation spectra were used to aid 
assignment where necessary. Samples were characterised by 
MALDI-TOF (positive reflectron mode) mass spectrometry, 
recorded on a Micromass Autospec-Q spectrometer. 80 
Analytical RP-HPLC was carried out on a Gilson system (234 
autoinjector, 322 series pumps, 155 UV/vis detector and 
controlled by the UnipointTM system interface) equipped with 
a Hichrom ACE 5 C18 250 × 4.6 mm analytical column. 
Semi-preparative RP-HPLC was carried out on a Gilson semi-85 
preparative RP-HPLC system (Anachem Ltd.) equipped with 
type 306 pumps and a Gilson 151 UV/vis detector. The system 
was fitted with a Hichrom ACE 5 C18 250 × 21.2 mm semi-
preparative column fitted with a SecurityGuardTM cartridge 
system, C18, 4 × 3.0 mm (Phenomenex). Buffers: Buffer A 90 
comprised 30 mM Tris, 2.5 mM DTT, 0.5 mM EGTA, pH 7.4; 
Buffer B comprised 30 mM Tris, 0.5 mM EGTA, 0.1% 
TRITON® X-100, pH 7.4; Buffer C comprised 50 mM 
Tris.HCl, pH 7.4, 200 mM sodium chloride and 0.1% 
TWEEN® 20; Buffer D comprised 50 mM Tris.HCl, pH 7.4, 95 
200 mM sodium chloride and 0.1% TWEEN® 20, complete 
EDTA-free protease inhibitor cocktail (1 tablet per 15 mL, 
Roche Diagnostics); Buffer E comprised 1 × phosphate 
 This journal is © The Royal Society of Chemistry [year] Journal Name, [year], [vol], 00–00  |  5 
buffered saline with 0.1% SDS and 0.1% TRITON® X-100. 
Organic Synthesis 
ω-Azido undecanoic acid (3):24 Sodium azide (1.37 g, 
21.1 mmol) was dissolved in a solution of 
11-bromoundecanoic acid (4.80 g, 17.5 mmol) in DMSO 5 
(200 mL). The clear colourless reaction mixture was stirred at 
room temperature overnight. The reaction mixture was diluted 
with water (80 mL) and to this was added HCl(aq) (1 M, 
30 mL) cautiously. Once the reaction mixture had cooled, the 
aqueous phase was extracted 3 × with EtOAc and the 10 
combined organic layers were washed 3 × with water and then 
brine before drying over MgSO4. After filtration, all volatiles 
were removed under reduced pressure to yield the crude 
product as a pale yellow oil. Purification by flash column 
chromatography (diethyl ether–n-hexane, 1:1, Rf = 0.38) gave 15 
the product as a waxy solid (3.05 g, 77% yield). δH/ppm 
(400 MHz, CDCl3) 1.24–1.43 (12H, m, (CH2)6), 1.55–1.72 
(4H, m, CH2CH2CO2H and CH2CH2N3), 2.36 (2H, t, J = 7.5 
Hz, CH2CO2H), 3.27 (2H, t, J = 7.0 Hz, CH2N3); δC/ppm 
(100 MHz, CDCl3) 24.7, 26.7, 28.9, 29.0, 29.1, 29.2, 29.3, 20 
29.4, 34.1, 51.5, 180.2 (C=O); m/z (MALDI-TOF –), 226 
([M – H]–). 
Tetradec-13-ynoic acid (4): To a solution of TMS-acetylene 
(1.26 mL, 8.95 mmol) in dry THF (7.0 mL) under nitrogen 
and cooled to –78 °C was added a solution of n-BuLi in 25 
hexanes (4.30 mL, 2.5 M, 10.74 mmol). The reaction mixture 
was allowed to warm up to room temperature for a few 
seconds before cooling to –78 °C. To this mixture was added 
a solution of 12-bromododecanoic acid (1.00 g, 3.58 mmol) in 
dry THF (20 mL) and dry HMPA (13 mL) dropwise. The 30 
reaction was allowed to warm to room temperature and stir 
until complete. Upon completion (after 18 hours, followed by 
TLC) the reaction mixture was returned to –78 °C and 
quenched by the addition of saturated NH4Cl(aq.). The aqueous 
layer was extracted with DCM (3 × 50 mL) and the combined 35 
organic layers were washed with brine (3 × 50 mL) before 
drying over MgSO4 and concentration under reduced pressure. 
The product was purified by flash column chromatography (n-
hexane–ethylacetate (1:1), Rf = 0.48). The TMS protected 
alkyne was taken up in MeOH (10 mL) and to this was added 40 
K2CO3 (192.2 mg). The reaction mixture was stirred at room 
temperature for 18 hours, after which time all volatiles were 
removed under reduced pressure and the residues partitioned 
between ethylacetate–HCl(aq.) (1:1, 60 mL). The aqueous 
phase was extracted with ethylacetate (3 × 30 mL) and the 45 
combined organic phases dried and concentrated as before. 
The product was isolated as clear colourless oil and required 
no further purification (199.3 mg, 25%). δH/ppm (400 MHz, 
CDCl3) 1.24–1.45 (14H, m, (CH2)7), 1.54 (2H, qi, J = 7.4 Hz, 
CH2CH2CO2H), 1.65 (2H, qi, J = 7.0 Hz, CH2CH2C≡CH), 50 
1.96 (1H, t, J = 2.6 Hz, C≡CH), 2.20 (2H, dt, J1 = 2.6 Hz, J2 = 
7.0 Hz, CH2C≡CH), 2.37 (2H, t, J = 7.5 Hz, CH2CO2H), 9.80 
(1H, bs, CO2H); δC/ppm (100 MHz, CDCl3) 18.4, 20.7, 24.7, 
28.5, 28.8, 29.1, 29.1, 29.2, 29.4, 29.5, 34.0, 68.1 (C≡CH), 
84.8 (C≡CH), 180.0 (CO2H) m/z (ESI-TOF –), 223 ([M – H]
–
55 
); HRMS, found 223.1710 (C14H23O2, [M – H]
–, requires 
223.1698). 
 ω-Azido undecanoic acid CoA thioester (5):24 To a stirring 
solution of ω-azido undecanoic acid 3 (15 mg, 64 mmol) in 
dry THF (1.0 mL) under nitrogen was added a solution of CDI 60 
(12 mg, 77 mmol) in DCM (1.0 mL). The reaction mixture 
was allowed to stir at room temperature for 30 minutes. After 
this, all volatiles were removed under reduced pressure. The 
resultant solids were taken up in dry THF (2.0 mL) and to this 
was added a solution of CoASH (50 mg, 64 mmol) in aqueous 65 
NaHCO3 (0.5 M, 5.0 mL). The reaction was allowed to stir at 
room temperature for 4 hours under nitrogen. After this time 
the THF was removed under reduced pressure and the 
remaining aqueous phase transferred in equal volumes to two 
12 mL centrifuge tubes. The addition of 20% perchloric acid 70 
resulted in the formation of an off white precipitate. The 
solids were pelleted by centrifugation and washed 3 × with 
acetone. Purification by preparative RP-HPLC by elution over 
a gradient of MeCN in 10 mM NH4OAc pH 5.2 (0–5 min 0% 
MeCN, 5–10 min up to 50% MeCN, 10–15 min 50% MeCN). 75 
Retention time = 23.3 min, detection was at 258 nm. The 
product was isolated as a white amorphous solid (11.4 mg, 
17% yield). δH/ppm (400 MHz, D2O) 0.70 (3H, s, CH3), 0.84 
(3H, s, CH3), 1.08–1.29 (12H, m, 6 × CH2), 1.41–1.54 (4H, m, 
CH2CH2CH2C(O)NH and CH2CH2N3), 2.34 (2H, s, SCH2), 80 
2.50 (2H, t, J = 7.2 Hz, (CH2)2CH2C(O)NH), 2.90 (2H, t, J = 
5.9 Hz, C(O)CH2CH2NH), 3.19 (2H, t, J = 6.9, CH2N3), 3.25 
(2H, bs, C(O)CH2CH2NH), 3.36 (2H, bs, SCH2CH2), 3.50 
(1H, bs, ½ × CH2(CH3)2), 3.77 (1H, bs, ½ × CH2(CH3)2), 3.95 
(1H, bs, C(O)CHOH), 4.16 (2H, bs, Rib-CH2), 4.51 (1H, bs, 85 
Rib-CH), 4.61–4.82 (2H, m, 2 × Rib-CH), 6.11 (1H, bd, J = 
4.2 Hz, CH(Pur)), 8.31 (1H, s, Ar-H), 8.57 (1H, s, Ar-H); m/z 
(MALDI-TOF –), 1040 ([(M + (NH4
+)3) – H]
–). 
Tetradec-13-ynoic acid CoA thioester (6): Following the 
above procedure (except using 4 (11.2 mg, 0.05 mmol), CDI 90 
(9.7 mg, 0.06 mmol) and CoASH (39.3 mg, 0.05 mmol)) the 
product was isolated as a white amorphous white solid 
(7.6 mg, 19%). δH/ppm (400 MHz, D2O) 0.69 (3H, s, CH3), 
0.84 (3H, s, CH3), 1.01–1.23 (14H, m, 7 × CH2), 1.31 (2H, qi, 
J = 7.0 Hz, CH2CH2C≡CH), 1.45 (2H, bs, 95 
CH2CH2CH2C(O)NH), 2.00 (2H, bs, CH2C≡CH), 2.09 (1H, s, 
C≡CH), 2.35 (2H, s, SCH2), 2.44 (2H, bs, 
(CH2)2CH2C(O)NH), 2.88 (2H, bs, C(O)CH2CH2NH), 3.22 
(2H, bs, C(O)CH2CH2NH), 3.36 (2H, bs, SCH2CH2), 3.51 
(1H, bs, ½ × CH2(CH3)2), 3.80 (1H, bs, ½ × CH2(CH3)2), 3.95 100 
(1H, bs, C(O)CHOH), 4.19 (2H, bs, Rib-CH2), 4.50 (1H, s, 
Rib-CH), 4.64–4.80 (2H, m, 2 × Rib-CH), 6.06 (1H, bd, J = 
4.8 Hz, CH(Pur)), 8.28 (1H, s, Ar-H), 8.54 (1H, s, Ar-H); that 
this compound did not generate satisfactory mass spectral data 
under ES (positive or negative mode), FAB or MALDI 105 
ionisation techniques. However, its purity (>95%) and identity 
were confirmed by proton NMR spectroscopy (see above) and 
by analytical RP-HPLC over a gradient of MeCN in 10 mM 
NH4OAc pH 5.2 (0–5 min 0% MeCN, 5–10 min up to 50% 
MeCN, 10–15 min 50% MeCN). Retention time = 15.3 min, 110 
detection was by UV absorbance at 258 nm. 
Solid-phase synthesis 
Peptide Synthesis (H2N-GLYVSRLFNRLFQKK-OH, 7):
27 
N--9-Fluorenylmethoxycarbonyl (Fmoc) protected amino 
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acids were obtained (Novabiochem) with the following side 
chain protecting groups: Arg(Pbf), Asn(Trt), Gln(Trt), Gly, 
Leu, Lys(Boc), Phe, Ser(tBu), Tyr(tBu) and Val were 
purchased from Novabiochem. O-(Benzotriazol-1-yl)-
N,N,N′,N′-tetramethyluronium hexafluorophosphate (HBTU) 5 
and Rink amide MBHA resin were purchased from Merck 
Biosciences. Peptide synthesis grade N,N-dimethylformamide 
(DMF) was purchased from Rathburn Chemicals and HPLC 
grade acetonitrile from Fischer. All other chemicals were 
purchased from Sigma-Aldrich Company Ltd. All reactions 10 
were carried out under an atmosphere of nitrogen. An 
Advanced ChemTech Apex 396 multiple peptide synthesiser 
(Advanced ChemTech Europe) was used for automated 
peptide synthesis. The peptides created in this study used Rink 
amide MBHA resin as the solid support (providing a 15 
C-terminal amide). Syntheses utilised 25 μmol resin per well 
and a standard Fmoc/tBu peptide synthesis strategy with DMF 
as solvent. The resin was swelled in DMF for one hour before 
proceeding with the cyclical steps of Fmoc deprotection (20% 
v/v piperidine in DMF), 3 × 5 min, washing (DMF, 5 × 1 min) 20 
and backbone elongation (coupling) mediated by HBTU and 
DIPEA (N,N'-diisopropylethylamine) (45 min). The coupling 
reaction used a 5-fold excess of amino acid to resin, 
1 equivalent of HBTU and 2 eq. DIPEA. The coupling stage 
was repeated twice for the attachment of the first amino acid 25 
to the resin. After elongation and final Fmoc deprotection, the 
resin was washed with 1 × 1 mL DMF, 3 × 1 mL DCM and 
3 × 1 mL MeOH before being allowed to dry in a desiccator 
overnight. Manual deprotection was accomplished by the 
addition of 1 mL of 95% TFA, 2.5% H2O and 2.5% 30 
triisopropyl silane (TIS) with thorough mixing by vortex. The 
supernatant was displaced through the frit into a 12 mL 
centrifuge tube and the beads washed in a similar manner with 
a further 0.5 mL TFA. The combined washings were treated 
with ~9.5 mL TBME (cooled to –20 °C) to precipitate the 35 
peptides. The solids were pelleted by centrifugation for 
15 min at 4300 rpm at 4 °C and washed (with vortexing and 
centrifugation) repeatedly in TBME (three times in total). The 
pelleted solids were dried in a desiccator overnight. The 
deprotected peptides were purified by semi-preparative 40 
RP-HPLC over a gradient of MeCN in 10 mM NH4OAc 
pH 5.2 (0–5 min 0% MeCN, 5–10 min up to 50% MeCN, 10–
15 min 50% MeCN). Detection was by UV absorbance at 
223 nm. The product (retention time 14.2 min) was obtained 
by lyophilisation as a white amorphous solid. m/z (MALDI-45 
TOF +), 1870 ([M+H]+). 
Azidomyristoylated Peptide Synthesis (AzMyr-NH-
GLYVSRLFNRLFQKK-OH, 8): The peptide was 
synthesised according to the procedure for 7, except for 
addition of activated acid after removal of the final Fmoc 50 
group. A solution of HBTU (500 μL, 0.5 M) in DMF was 
added to a solution of 3 (125 μmoles in DMF, 0.5 M) and 
DIPEA (1.5 mL, 0.5 M). The resultant mixture was vortexed 
thoroughly for 15 min before addition to the appropriate well 
of the peptide synthesiser. The peptide was then washed and 55 
cleaved and purified as detailed above. The product (retention 
time 20.2 min) was recovered by lyophilisation as a white 
amorphous solid. m/z (MALDI-TOF +), 2078 ([M+H]+). 
Alkynylmyristoylated Peptide Synthesis (YnMyr-NH-
GLYVSRLFNRLFQKK-OH, 9): The peptide was prepared 60 
as for 8 except using 4 (125 μmoles in DMF, 0.5 M). The 
product (retention time 20.9 min) was recovered by 
lyophilisation as a white amorphous solid. m/z (MALDI-TOF 
+), 2075 ([M+H]+). 
N-(15-Oxo-19-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-65 
4-yl)-4,7,10-trioxa-14-azanonadecyl)pent-4-ynamide 
(Alkynyl capture reagent, 13): Biotin-PEG NovaTagTM resin 
(0.48 mmol g–1 loading, 52.1 mg, 25 μmol,) was deprotected 
(Fmoc) by treatment with 20% v/v piperidine in DMF before 
addition of pent-4-ynoic acid 10 (12.3 mg, 125 μmol), HATU 70 
(47.5 mg, 125 μmol) and DIPEA (43.5 μL) in DMF (2 mL). 
The crude product was cleaved from the resin by treatment 
with 95% TFA and purified by semi-preparative RP-HPLC 
over a gradient of MeCN (0.1% TFA) in H2O (0.1% TFA) (0–
1 min 30% MeCN, 1–30 min up to 100% MeCN, 30–35 min 75 
100% MeCN). Detection was at 220 nm. The product was 
obtained by lyophilisation as a white amorphous solid 
(6.3 mg, 48% yield). δH/ppm (500 MHz, CDCl3) 1.49 (2H, qi, 
J = 7.8 Hz, biotin CH2), 1.64–1.85 (8H, m, biotin CH2 × 2 and 
NHCH2CH2CH2O × 2), 2.02 (1H, t, J = 2.6 Hz, C≡CH), 2.22 80 
(2H, t, J = 7.4 Hz, biotin NHC(O)CH2), 2.42 (2H, t, J = 
7.3 Hz, CH2CH2C≡CH), 2.55 (2H, dt, J = 7.3, 2.5 Hz, 
CH2C≡CH), 2.77 (1H, d, J = 12.8 Hz, biotin ½ × SCH2), 2.95 
(1H, dd, J = 12.8, 5.0 Hz, biotin ½ × SCH2), 3.18 (1H, dt, J = 
7.3, 5.6 Hz, SCH), 3.39 (4H, qi, J = 6.1 Hz, 2 × PEG 85 
CH2NH), 3.57–3.71 (12H, m, 6 × PEG CH2), 4.36 (1H, dd, J = 
7.5, 4.7 Hz, biotin SCHCH), 4.54 (1H, dd, J = 7.6, 4.9 Hz, 
biotin SCH2CH), 5.14 (1H, bs, NH), 5.96 (1H, bs, NH), 6.57 
(2H, m, 2 × PEG–NHCO); δC/ppm (125 MHz, CDCl3) 15.0, 
25.6, 28.1, 29.0, 35.3, 35.4, 36.0, 37.8, 40.6, 55.5, 60.1, 61.9, 90 
69.2, 69.9, 70.0 (4 × CH2), 70.2, 70.5 (2 × CH2), 83.3, 163.4, 
171.0, 173.0; m/z (ESI-TOF +), 549 ([M + Na]+), 527 ([M + 
H]+); HRMS, found 527.2921 (C25H43N4O6S, [M + H]
+, 
requires 527.2903). 
N-(18-Azido-15-oxo-4,7,10-trioxa-14-azaoctadecyl)-5-(2-95 
oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide 
(Azido capture reagent, 14): Synthesis and purification as 
13, except for addition of 4-azidobutanoic acid 11 (16.1 mg, 
125 μmol). The product was obtained by lyophilisation as a 
white amorphous solid (6.3 mg, 45% yield). δH/ppm 100 
(500 MHz, CDCl3) 1.46 (2H, q, J = 7.4 Hz, biotin CH2), 1.62–
1.83 (8H, m, biotin CH2 × 2 and NHCH2CH2CH2O × 2), 1.92 
(2H, qi, J = 7.2 Hz, CH2CH2N3), 2.20 (2H, t, J = 7.3 Hz, 
biotin NHC(O)CH2), 2.26 (2H, t, J = 7.3 Hz, CH2CH2CH2N3), 
2.74 (1H, d, J = 12.6 Hz, biotin ½ × SCH2), 2.92 (1H, dd, J = 105 
12.8, 5.0 Hz, biotin ½ × SCH2), 3.15 (1H, dt, J = 7.3, 5.6 Hz, 
SCH), 3.39 (6H, m, 2 × PEG CH2NH and CH2N3), 3.54–3.68 
(12H, m, 6 × PEG CH2), 4.33 (1H, dd, J = 7.5, 4.7 Hz, biotin 
SCHCH), 4.51 (1H, dd, J = 7.6, 4.9 Hz, biotin SCH2CH), 5.15 
(1H, bs, NH), 5.95 (1H, bs, NH), 6.54 (2H, m, 2 × PEG–110 
NHCO); δC/ppm (125 MHz, CDCl3) 24.9, 25.6, 28.1, 29.0, 
33.2, 35.9, 35.9, 37.8, 38.0, 40.6, 51.0, 55.5, 60.2, 61.9, 69.9, 
70.0 (3 × CH2), 70.2, 70.4, 70.5, 163.5, 172.0, 173.0; m/z 
(MALDI-TOF +), 580 ([M + Na]+), 558 ([M + H]+); HRMS, 
found 558.3074 (C24H44N7O6S, [M + H]
+, requires 558.3074). 115 
Methyl 2-(diphenylphosphino)-4-(15-oxo-19-(2-
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oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-4,7,10-
trioxa-14-azanonadecylcarbamoyl)benzoate (Staudinger-
Bertozzi Capture Reagent, 16): Synthesis and purification as 
13, except for addition of 3-(diphenylphosphino)-4-
(methoxycarbonyl) benzoic acid 1240 (16.1 mg, 125 μmol). 5 
The product was obtained by lyophilisation as a white 
amorphous solid (9.9 mg, 50% yield). δH/ppm (400 MHz, 
CDCl3) 1.43 (2H, q, J = 7.6 Hz, biotin CH2), 1.60–1.87 (8H, 
m, biotin CH2 × 2 and NHCH2CH2CH2O × 2), 2.19 (2H, dt, 
J = 1.6, 7.1 Hz, biotin NHC(O)CH2), 2.74 (1H, d, J = 12.9 Hz, 10 
biotin ½ × SCH2), 2.91 (1H, dd, J = 4.9, 12.9 Hz, biotin 
½ × SCH2), 3.15 (1H, dt, J = 4.7, 7.4 Hz, biotin SCH), 3.33 
(2H, app. q, J = 5.9 Hz, CH2NHC(O)CH2), 3.41–3.66 (14H, 
m, 6 × PEG CH2 and ArC(O)NHCH2), 3.75 (3H, s, OCH3), 
4.33 (1H, dd, J = 4.6, 7.5 Hz, biotin SCHCH), 4.52 (1H, dd, J 15 
= 4.9, 7.7 Hz, biotin SCH2CH), 5.53 (1H, bs, NH), 6.24 (1H, 
bs, NH), 6.55 (1H, bs, NH), 7.01 (1H, bt, J = 4.1 Hz, NH), 
7.26–7.38 (10H, m, PPh2), 7.42 (1H, dd, J = 1.5, 3.7 Hz, Ar-
H), 7.79 (1H, dd, J = 1.5, 8.0 Hz, Ar-H), 8.09 (1H, dd, 
J = 3.7, 8.0, Ar-H); δC/ppm (100 MHz, CDCl3) 8.5, 25.5, 28.1, 20 
28.3, 31.5, 35.7, 39.7, 45.8, 52.3, 55.6, 60.4, 61.9, 68.8, 69.7, 
69.8, 70.0, 70.1, 70.3, 126.8, 128.6, 128.7, 128.9, 129.0, 
130.8, 133.0, 133.8, 134.0, 136.5, 136.7, 137.2, 141.1, 141.4, 
162.7, 164.5, 166.6, 166.8, 173.9; δP/ppm (162 MHz, CDCl3) 
–3.77 (1P, s, PPh2), 32.67 (1P, s, P(O)Ph2), oxidised to 25 
unoxidised ~1:50 by peak integration; m/z (MALDI-TOF +), 
815 ([M + Na]+), 793 ([M + H]+), 245 (biotin fragment); 
HRMS, found 793.3403 (C41H54N4O8SP, [M + H]
+, requires 
793.3400). IMPORTANT NOTE: DMSO stocks of 16 were 
found to be 90% oxidised to the corresponding phosphine 30 
oxide (by analytical RP-HPLC) after 1 month of constant use. 
To ensure the quality of 16 used in capture experiments, once 
a DMSO stock had been made up it was thoroughly de-gassed 
with helium, aliqotted into 20 μL portions and stored at –20 
°C under N2(g). 35 
HPLC transfer assay 
Stock solutions containing azidomristoyl–CoA 4 (20 mM in 
10 mM NaOAc pH 5.0–EtOH, 1:1), peptide 5 (20 mM in H2O) 
and CaNMT (50 μM in buffer A, 20% glycerol) were 
prepared. Transfer reactions were carried out as follows: To 40 
buffer A (115 μL) was added CaNMT (1 μL), azidomyristoyl–
CoA 4 (5 μL) and peptide (5 μL), mixed thoroughly and the 
reactions incubated at 37 °C. Samples were taken at 0 h, 1 h, 
and 18 h. Sampling involved taking a 25 μL aliquot of the 
reaction mixture and quenching this into 25 μL of methanol, 45 
the resultant solution was analysed by HPLC over a gradient 
of MeCN (0.1% TFA) in H2O (0.1% TFA) (0–2 min 2% 
MeCN, 2–25 min up to 100% MeCN, 25–35 min 100% 
MeCN). Detection was at 223 nm. 
Protein expression and in vivo tagging 50 
Recombinant CaNMT and PfARF1: CaNMT was cloned 
into pET11c (ampicillin resistance), expressed in E. coli and 
purified as described.27 PfARF1 wild-type and G2A mutant 
proteins were cloned into pET28a (kanamycin resistance), 
expressed in E. coli and purified as reported previously.27 55 
Preparation of soluble cell extracts: BL21 (DE3) competent 
cells (Stratagene) were co-transformed with pET11c-CaNMT 
and pET28a-PfARF1 (wild type) or PfARF1 (G2A mutant). 
Single transformations of each plasmid were performed as 
negative controls. A single colony of transformed cells was 60 
used to inoculate fresh Luria-Bertani media supplemented 
with the relevant selection antibiotics. Cells were incubated at 
37 C with shaking. At mid-log phase, protein expression was 
induced with 1 mM final IPTG, and the culture medium was 
supplemented with the appropriate acid (stock in DMSO) to a 65 
final concentration of 500 µM. Cells were induced for 4 hours 
at 37 C with shaking. Cells were harvested by centrifugation 
and washed 3 times with buffer D. Cells were lysed by adding 
BugBuster® reagent (Novagen) supplemented with benzonase 
(Sigma-Aldrich). Soluble extracts were separated by 70 
centrifugation (17,000 × g, 30 m, 4 C). Total protein content 
was determined by the Bradford method using bovine serum 
albumin (BSA) as a standard. 
In vivo Assay: To an aliquot of cell lysate containing 40 μg 
protein was added 0.3 μL capture reagent stock solution 75 
(10 mM in DMSO, 50 μM final), 6 μL TCEP stock solution 
(10 mM in H2O, 1 mM final), 0.6 μL triazolyl ligand (10 mM 
in DMSO, 100 μM final), 6 μL CuSO4 stock (10 mM in H2O, 
1 mM final) and the volume adjusted to 60 μL with buffer E if 
required. The resultant reaction mixtures were adgitated at 80 
room temperature in a carousel for 1 hour. Two 15 μL aliquots 
were taken for SDS-PAGE (for detection of the His6 tag and 
of biotin) with the same volume left for repeat analysis if 
required. 
Gel-based analysis 85 
SDS PAGE: Proteins were separated by SDS-PAGE using 
1 mm Bis-Tris gels (4% stacking gel, 12% resolving gel) in 
NuPAGE® MES SDS running buffer (Invitrogen). Samples 
were prepared by boiling for 5 minutes in NuPAGE® LDS 
sample loading buffer (4 ×). BenchMarkTM prestained protein 90 
ladder (Invitrogen) and biotinylated protein ladder (Cell 
Signaling Technology) were used for molecular weight 
comparison as appropriate.  
Immunoblotting: Proteins were transferred from PAGE gels 
to HybondTM-ECLTM nitrocellulose membranes (Amersham 95 
Biosciences) using a semi-dry electrophoretic transfer method. 
The membranes were blocked for 1 hour in BSA (5% in buffer 
C) before washing for 3 × 10 min in buffer C. The blots were 
probed using the appropriate antibody–HRP conjugate (anti-5 
× His or NeutrAvidinTM) at 1:5000 dilution in buffer C for 100 
1 hour at room temperature. The membranes were then 
washed with buffer C for 3 × 5 min before detection using the 
enhanced chemiluminescence (ECL) kit according to the 
manufacturer’s instructions (Amersham Biosciences). 
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† We have previously shown that a recombinant protein can be tagged in 
vitro using CaNMT. In this instance tagging of protein proceeds in a 
similar manner to tagging of the peptide substrates described above.13 
‡ Note that in our previous work13 we deliberately depleted the lysate of 10 
this biotinylated protein prior to capture; this step may be omitted for 
convenience as in the present report. 
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